Last update 06 Dec 2024
Granisetron Hydrochloride
Last update 06 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Azasetron Hydrochloride and Sodium Chloride, Granisertron Hydrochloride, Granisetron HydrochIoride + [48] |
Target |
Mechanism 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (29 Dec 1993), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC18H25ClN4O |
InChIKeyQYZRTBKYBJRGJB-WQTKJZBYSA-N |
CAS Registry107007-99-8 |
Related
22
Clinical Trials associated with Granisetron Hydrochloride盐酸格拉司琼片（1 mg）在健康受试者中随机、开放、两制剂、单次给药、四周期、完全重复交叉空腹和餐后状态下生物等效性试验
[Translation] A randomized, open-label, two-dose, single-dose, four-period, completely repeated crossover bioequivalence study of granisetron hydrochloride tablets (1 mg) in healthy subjects under fasting and fed conditions
盐酸格拉司琼片（1 mg）在健康人体内三周期参比制剂部分重复餐后生物等效性研究
[Translation] A three-cycle repeated-meal bioequivalence study of granisetron hydrochloride tablets (1 mg) with a reference formulation in healthy volunteers
Role of Granisetron in Preventing Hypotension After Spinal Anesthesia With Levobupivacaine in Rheumatic Patients Undergoing Elective Cesarean Section: A Randomized Clinical Trial
100 Clinical Results associated with Granisetron Hydrochloride
Login to view more data
100 Translational Medicine associated with Granisetron Hydrochloride
Login to view more data
100 Patents (Medical) associated with Granisetron Hydrochloride
Login to view more data
261
Literatures (Medical) associated with Granisetron Hydrochloride03 Jul 2024Drug and chemical toxicology
Effects of taxifolin on tramadol-induced oxidative and inflammatory liver injury in rats: an experimental study
Article
Author: Subaşı, Faruk ; Mokhtare, Behzad ; Eren, Nurhan ; Ölmeztürk Karakurt, Tülay Ceren ; Çoban, Taha Abdulkadir ; Süleyman, Halis ; Kuyrukluyıldız, Ufuk
In this experimental study we aimed to investigate the biochemical and histopathological effects of concomitantly administered taxifolin on tramadol-induced liver damage in rats. The rats were divided into three groups; control group (CG), tramadol alone (TRG), and taxifolin + tramadol given (TTRG) groups. Malondialdehyde (MDA), total glutathione (tGSH), total oxidant status (TOS), total antioxidant status (TAS), nuclear factor-kappa beta (NF-kB), tumor necrosis factor-α (TNF-α), and interleukin-1β (IL-1β) levels were measured in liver tissues. Liver tissues were also examined histopathologically. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities were determined in blood samples. In tissue analyses, determinants of oxidative stress and inflammation, all were significantly higher in the TRG group compared with the control and TTRG groups. In the TTRG group, all oxidative stress and inflammation markers were significantly lower than in the TRG group. In addition, there was not any significant difference between the control and TTRG groups regarding the TOS and TAS status. Serum liver enzymes were also significantly higher in the TRG group than in the other two groups. In histopathological examinations, the control group had a normal histological appearance. Degenerative-necrotic hepatocytes and hemorrhage, which were seen at a severe level in the TRG group, were found to be moderate in the treated TTRG group. In addition, mononuclear cell infiltrations were found to be severe in the TRG group and mild in the treated TTRG group. Finally it was concluded that Taxifolin alleviated the toxic effects of tramadol on the liver including the histopathological and biochemical changes as well as the oxidative damage.
01 Jul 2024Annals of surgical oncology
Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases
Review
Author: Laroche, Sophie ; Charlotte, Frederic ; Fuks, David ; Bachet, Jean-Baptiste ; Lim, Chetana ; Scatton, Olivier ; Goumard, Claire
BACKGROUND:
Optimal management of colorectal liver metastasis (CRLM) is based on a combination of chemotherapy and surgical resection. The tumor regression grade (TRG) score is a histological scoring system to evaluate response to chemotherapy. The prognosis of a heterogeneous response in cases of multiple metastases has not been evaluated according to the TRG score.
PATIENTS AND METHODS:
All patients who underwent liver resection for multiple CRLM after neoadjuvant chemotherapy in two tertiary centers from January 2015 to April 2019 were retrospectively included. Oncological characteristics and outcome between TRG 1-2-3 (good response group), TRG 4-5 (poor response group) and heterogeneous TRG (good and poor TRG among different lesions within the same patient) groups were compared.
RESULTS:
Among the 327 patients included, 134 (41.0%) had good response (TRG 1-2-3), 120 (36.7%) had poor response (TRG 4-5), and 73 (22.3%) had heterogeneous response. The type and number of cycles of chemotherapy, k-Ras mutational status, and tumor number or size did not differ between the three groups. Use of irinotecan-based and anti-VEGF neoadjuvant therapy was associated with better TRG response [irinotecan-based: hazard ratio (OR) = 1.744; p = 0.045; anti-VEGF neoadjuvant therapy: 2.054; p = 0.005). Overall survival (OS) was higher in the 1-2-3 TRG group than in the heterogeneous TRG group (2-year OS = 81.3% vs. 60.3%, respectively; p = 0.003) and the 4-5 TRG group (2-year OS = 81.3% vs. 55.0%, respectively; p = 0.012) and similar between the heterogeneous and 4-5 TRG groups.
CONCLUSIONS:
The proportion of heterogeneous pathological response according to TRG is 22.3%, and the prognosis is comparable to that of poor pathological response.
01 Jun 2024Journal of Gastrointestinal Cancer
Treatment Response to Neoadjuvant Therapy in Squamous Esophageal Cancer-Correlation Between Metabolic Response and Histopathology.
Article
Author: Kaderi, Abdeali Saif Arif ; Pawar, Akash ; Tiwari, Virendra Kumar ; Niyogi, Devayani ; Sabita, Jiwnani
PURPOSE:
Esophageal cancer is among the leading causes of cancer-related mortality worldwide. Patients presenting with localized and loco-regionally advanced cancer without distant metastases have reasonable survival with multimodality management. Adequate and comprehensive staging is the backbone for proper selection of patients fit for curative treatment. Positron emission tomography (PET) in combination with contrast-enhanced computed tomography (CECT) is utilized as the standard staging modality. Multimodality treatment has been able to achieve evaluable tumor responses including pathological complete response (pCR). It is, therefore, necessary to understand whether the impact of neoadjuvant therapy can be evaluated on imaging, i.e., standardized uptake value (SUV) on PET scan done for response assessment and if this can be correlated with histopathological response and later, with survival. Squamous cell carcinoma (SCC) is more common globally and in the Indian subcontinent; hence, we chose this subgroup to evaluate our hypothesis.
METHODS:
This is a single institution, retrospective study. Out of the 1967 patients who were treated between 2009 and 2019, 1369 (78.54%) patients had SCC. Out of these, 44 received NACTRT, whereas 1325 received NACT followed by curative surgery. The standardized uptake value (SUV) of 18-fluorodeoxyglucose was recorded during pre- and post-neoadjuvant treatment (NAT) using positron emission tomography (PET). The histopathology of the final resection specimen was evaluated using the Mandard tumor regression grade (TRG) criteria with response being graded from 0 to 5 as no residual tumor (NRT), scanty residual tumor (SRT), and residual tumor We attempted to find a cut-off value of the post neoadjuvant SUV of the primary tumor site which correlated with achievement of better histopathological response.
RESULTS:
Out of 1325 patients of SCC esophagus who underwent surgery, 943 patients had available data of TRG, and it was categorized into the 0-2 category which had 325 patients (34.5%) and 3-5 category, 618 patients (65.5%). The SUV was taken only from the PET scans done at our institution, so as to achieve a more homogenous cohort, and this was available for 186 patients, 151 from the NACT group and 35 from the NACTRT group. The ROC method was used to find the cut-off for SUV (5.05) in the NACT cohort, which depicted significant difference in the outcome. Out of these, 93 patients who underwent NACT had SUV > 5.05 and 58 had SUV < 5.05. It was found that the subjective and objective histopathological scores correlated at a p value of < 0.0001. Specifically, the majority of cases with SRT tended to be in the 3-5 category of TRG, whereas cases with NRT are predominantly in the 0-2 category. In the ≥ 5.05 category of SUV, there were 76 cases with SRT. In the NACT cohort, the < 5.05 category of SUV, there are 26 cases with SRT and 32 cases with NRT. Among cases with SRT, 74.5% had SUV ≥ 5.05, while 25.5% had SUV < 5.05. Among cases with NRT, 34.7% had SUV ≥ 5.05, while 65.3% had SUV < 5.05 (p value 0.007). No significant association was found in the radio-pathological correlation in the NACTRT group.
CONCLUSION:
Our study confirms the correlation of post neoadjuvant chemotherapy PET SUV with histopathological response, the cut-off of SUV being 5.05 in our cohort. This confirms the predictive value of FDG PET as demonstrated in other studies. Furthermore, its prognostic value with respect to survival has been verified in multiple other studies. With larger scale randomized studies, we may be able to identify the group of patients who have borderline operability anatomically as well as physiologically, where alternative treatment regimens may be indicated to improve outcomes.
100 Deals associated with Granisetron Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00677 | Granisetron Hydrochloride | - |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Radiation-induced nausea and vomiting | JP | 22 Dec 2011 | |
| Chemotherapy-induced nausea and vomiting | JP | 30 Jun 1995 | |
| Nausea | US | 29 Dec 1993 | |
| Neoplasms | US | 29 Dec 1993 | |
| Postoperative Nausea and Vomiting | US | 29 Dec 1993 | |
| Vomiting | US | 29 Dec 1993 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Carcinoma | Phase 1 | CN | 17 Jan 2014 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 189 | Placebo (Placebo Group) | mxbdqliewe(cnbnwfvmaz) = nrxniowyyp ocvtjijltp (fpscsamzkh, jeguobcqef - rujialjlas) View more | - | 19 Nov 2014 | ||
Placebo+SyB D-0701 (SyB D-0701: Low Dose Group) | mxbdqliewe(cnbnwfvmaz) = humzlkmnvh ocvtjijltp (fpscsamzkh, dyrksmzjgg - yvnsfuezsq) View more | ||||||
Not Applicable | 40 | rwvcugydlm(zehfwbzpig) = cbzfenofhb irwpebduxd (zmyokyltbp, ukfnobvgky - tfubycgbgu) View more | - | 03 Oct 2014 | |||
Phase 3 | 1,021 | (Arm II) | qrogbdoirg(nzkynimmxa) = btpadceuur brgtzkyavy (hspmgroovk, lpyvzbqfzm - udwkqvhdoa) View more | - | 03 Nov 2013 | ||
(Arm III) | qrogbdoirg(nzkynimmxa) = wwmwdscjfz brgtzkyavy (hspmgroovk, soxomwdnfg - mugmojdlmi) View more | ||||||
Phase 1 | - | 40 | (Granisetron) | vpwnvctuif(dlzgiztvgl) = rvvqkaejfq ayirfelcnt (adaikiaoph, gllnhqphvj - efwtjvlzix) View more | - | 04 Aug 2009 | |
(Kytril®) | vpwnvctuif(dlzgiztvgl) = usizrwmrer ayirfelcnt (adaikiaoph, bqdiffrbku - lstoooxigi) View more | ||||||
Phase 1 | - | 80 | (Granisetron) | aqpcfvpcap(lzgllmfqdh) = vgvglqbrqf zueunllnoy (jsojtvgwun, psrxesbpah - nrbzfdgkby) View more | - | 04 Aug 2009 | |
(Kytril®) | aqpcfvpcap(lzgllmfqdh) = zovisodjnk zueunllnoy (jsojtvgwun, fqglxmgxvy - xdyeymbzvt) View more | ||||||
Phase 3 | - | sxayksmqpz(nkpgmnlxtw) = ncaketghdd mpioqvpfxl (tnzixufgme ) View more | - | 20 May 2009 | |||
sxayksmqpz(nkpgmnlxtw) = ljbbbigcjw mpioqvpfxl (tnzixufgme ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free